BACKGROUND. Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome, and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.

中文翻译：

---

晚期前列腺癌的 RNASEH2B 丢失和 PARP 抑制


背景。 临床试验表明，PARP 抑制的抗肿瘤活性超越了同源重组缺陷 （HRD）。RNASEH2B丢失与 HRD 无关，并且在临床前对 PARP 抑制敏感。目前的研究报告了晚期前列腺癌中 RNASEH2B 蛋白丢失及其与 PARP 抑制治疗期间 RB1 蛋白丢失、临床结果和前瞻性临床试验中克隆动力学的相关性。